More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Pride Flag Removed From Stonewall National Monument Sparks Backlash and Protest Plans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Novocure (NASDAQ: NVCR) stock soared more than 30% in extended trading Wednesday after the U.S. Food and Drug Administration (FDA) approved its Optune Pax device for the treatment of locally advanced pancreatic cancer. The regulatory milestone marks a significant advancement for the company and introduces a new therapeutic option for patients battling one of the deadliest forms of cancer.
Optune Pax is a wearable, portable medical device designed to be used alongside chemotherapy drugs gemcitabine and nab-paclitaxel. The system delivers Tumor Treating Fields (TTFields), a therapy that uses alternating electric fields to disrupt cancer cell division. By interfering with tumor growth and triggering cancer cell death, TTFields therapy targets malignant cells while minimizing damage to healthy tissue.
Following the FDA approval announcement, NVCR shares jumped to $13.80 by 20:19 ET, after rising more than 50% earlier in after-hours trading. The sharp increase in Novocure stock reflects strong investor confidence in the commercial potential of Optune Pax and its role in expanding pancreatic cancer treatment options.
The FDA’s decision was supported by data from the Phase 3 PANOVA-3 clinical trial, which included 571 patients with locally advanced pancreatic cancer. Results demonstrated a meaningful improvement in overall survival compared to chemotherapy alone. The study also showed a significant delay in pain progression and higher one-year survival rates for patients treated with the combination of TTFields therapy and standard chemotherapy.
Importantly, safety results were broadly comparable between the treatment and control groups, reinforcing the therapy’s tolerability profile. With this approval, Novocure strengthens its oncology portfolio and positions Optune Pax as a promising new standard of care in advanced pancreatic cancer treatment, a space with urgent unmet medical needs.
